Research Centers in Minority Institutions (UTSA) Institute for Integration of Medicine & Science (UTHSA) & UTSA UTHSA Joint Graduate Program in Biomedical Engineering invite vou to attend

STRECH Seminars in Translational Research

Presents

The Biosignatures of Treatment Response in Depression

Currently, there are no valid clinical or biological markers to inform treatment selection for depressed patients. Recent evidence suggests that there are several potential biomarkers that may personalize selection amongst antidepressant medications with different mechanisms of action. Recent large studies have used blood-based markers, neuroimaging, and EEG to examine predictors and moderators to treatments for depression. The Combining Medications to Enhance Depression Outcomes (CO-MED) trial included adults with major depressive disorder (MDD) who provided plasma samples and were treated with either escitalopram-plus-placebo,

bupropion-plus-escitalopram, or venlafaxine-pus-mirtazapine. Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) trial included participants with MDD who were randomized to sertraline or placebo for 8 weeks, and provided blood, MRI, and EEG data. This presentation will review the recent biomarker results to date, with an emphasis on new findings from the CO-MED and EMBARC trials.




Madhukar Trivedi, M.D.

Founding Director, Center for Depression Research and Clinical Care Peter O Donnell Jr Brain Institute Betty Jo Hay Distinguished Chair in Mental Health Julie K, Hersh Chair for Depression Research and Clinical Care Professor of Psychiatry Chief, Division of Mood Disorders PI. Texas Node of the NIDA Funded Clinical Trials Network UT Southwestern Medical Center at Dallas









Medical School (MED) 309L

For more information scan the QR code or contact us at STRECH@UTHSCSA.edu (210) 562-IIMS

